Does Phenytoin Deplete Folate? What the Research Says

Yes, phenytoin is one of the most potent folate-depleting medications in clinical use. This interaction has been recognized since the 1960s and remains clinically significant today. Phenytoin interferes with folate at multiple levels: it blocks intestinal absorption of dietary folate, induces hepatic enzymes that accelerate folate catabolism, and may directly inhibit folate-dependent enzymes. Up to 75% of patients on chronic phenytoin therapy develop subnormal serum folate levels, making this one of the highest-frequency drug-nutrient depletions documented in clinical medicine. The consequences extend beyond simple vitamin deficiency, as folate depletion can cause megaloblastic anemia, elevated homocysteine, neural tube defects in pregnancy, and cognitive impairment.

PubMed indexes 4,882 articles related to phenytoin, with 20 meta-analyses addressing its metabolic effects. The CTD knowledge graph documents extensive gene interactions between phenytoin and folate metabolism pathways, including direct effects on CYP2C9 (with a Css/IC50 ratio of 3.0x at standard oral doses). ChEMBL clinical trial data spans 35 therapeutic indications for phenytoin, providing broad safety surveillance across diverse patient populations. Folate biomarker tracking across 801 compounds in the knowledge graph confirms phenytoin as a primary depleting agent. Cross-referencing FAERS adverse event reports reveals a consistent pattern of megaloblastic anemia and peripheral neuropathy in chronic phenytoin users, symptoms that resolve with folate supplementation. The evidence base is so strong that folate monitoring is now considered standard of care for phenytoin prescriptions.

Phenytoin depletes folate through three simultaneous mechanisms. First, it competitively inhibits the intestinal enzyme folate conjugase (gamma-glutamyl hydrolase), which converts dietary polyglutamate folate into the monoglutamate form required for absorption. This directly reduces folate uptake from food. Second, phenytoin induces hepatic cytochrome P450 enzymes and other metabolic pathways that accelerate folate breakdown, increasing daily folate requirements. Third, phenytoin may interfere with folate transport proteins that carry folate across cell membranes and into the cerebrospinal fluid, potentially contributing to the cognitive effects seen in some patients. The combined effect of reduced absorption and accelerated metabolism creates a supply-and-demand mismatch that depletes folate stores within weeks to months of initiating therapy, faster than most other drug-nutrient interactions.

If you take phenytoin, folate supplementation is strongly recommended by neurological practice guidelines. L-methylfolate (the active form) at 1-5 mg daily is preferred over folic acid because it bypasses the metabolic steps that phenytoin disrupts. However, folate supplementation requires careful medical supervision with phenytoin because high-dose folate can increase phenytoin metabolism, potentially reducing seizure control. Your neurologist should monitor both serum folate and phenytoin levels together. Request serum folate testing along with homocysteine levels at baseline and every 6 months during therapy. Folate-rich foods include dark leafy greens, legumes, asparagus, and fortified grains. Women of childbearing age on phenytoin face particular urgency because folate depletion dramatically increases neural tube defect risk, making preconception planning essential.